Article
Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma.
Journal of translational medicine - 14 Jan 2020
Li Ying, Jiang Wenbin, Li Tianhao, Li Mengyue, Li Xin, Zhang Zheyang, Zhang Sainan, Liu Yixin, Zhao Wenyuan, Gu Yunyan, Qi Lishuang, Ao Lu, Guo Zheng
Abstract excerpt
BACKGROUND: Immune checkpoint inhibitors are effective in some cases of lung adenocarcinoma (LUAD). Whole-exome sequencing has revealed that the tumour mutation burden (TMB) is associated with clinical benefits among patients from immune checkpoint inhibitors. Several commercial mutation panels have been developed for estimating the TMB regardless of the cancer type. However, different cancer types have different...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.